Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis
2023-506656-24-00Phase 3Authorised
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and prednisone in myasthenia gravis (MG) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Planned start Mar 2024; status: authorised.
02
Drugs
rituximabprednisone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-506656-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506656-24-00.